AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas

Regulatory information

AMBLor is in the process of completing UK Conformity Assessed marking class IVDR for in vitro diagnostic devices. This is expected in mid-2022. Its component antibodies are approved by UK Accreditation Services for the send-away service with Newcastle upon Tyne NHS Hospital Trust.